Home / Peptides / ARA-290
Investigational

ARA-290 — Cibinetide

Neuropathic Pain & Tissue Protection. ARA-290 (cibinetide) is a synthetic peptide derived from erythropoietin (EPO) that selectively activates the innate repa...

Sequence
11 Amino Acids
Category
Investigational
Primary Use
Neuropathic Pain
Administration
SubQ

What Is ARA-290?

ARA-290 (cibinetide) is a synthetic peptide derived from erythropoietin (EPO) that selectively activates the innate repair receptor (IRR) — a heterodimer of the EPO receptor and the β-common receptor. Unlike EPO itself, ARA-290 does not stimulate red blood cell production, avoiding the thrombotic risks associated with EPO while retaining its tissue-protective and anti-inflammatory properties.

neuropathy tissue protection EPO-derived anti-inflammatory pain

Mechanism of Action

ARA-290 activates the innate repair receptor, triggering anti-inflammatory and tissue-protective signaling cascades without stimulating erythropoiesis. This selective activation promotes nerve fiber repair, reduces inflammatory cytokines, and supports tissue healing. The separation of tissue-protective from erythropoietic effects makes it a targeted therapeutic approach.

Key Research Findings

  • Neuropathic pain — Clinical trials in sarcoidosis patients showed significant improvement in small nerve fiber density and pain scores
  • Diabetic neuropathy — Phase II data suggests improvements in corneal nerve fiber density and neuropathy symptoms
  • Type 2 diabetes — Studies show metabolic improvements including reduced HbA1c
  • Tissue repair — Preclinical evidence of accelerated healing in various tissue injury models
  • Anti-inflammatory — Documented reduction in inflammatory markers across multiple clinical settings

Important: The evidence base for ARA-290 varies by application. Many findings are from preclinical (animal or in vitro) studies. Large-scale human clinical trials may not be completed. Always evaluate the quality of evidence before drawing conclusions.

Known Side Effects

Generally well-tolerated in clinical trials. Injection site reactions are the most commonly reported effect. No significant hematological effects (unlike EPO). Long-term safety data continues to be collected.

Legal Status (2026)

ARA-290 (cibinetide) is an investigational compound that has been in clinical trials. Not FDA-approved. Available as a research chemical from select suppliers.

Where to Buy ARA-290 for Research

These verified suppliers carry ARA-290 with third-party COAs and US-based shipping.

BP
BioPure Peptides
USA-made · 99%+ purity · WHO/GMP certified
  • Third-party tested with COAs on every batch
  • Ships from Chandler, AZ — free shipping over $200
  • 30+ peptides in catalog including blends and stacks
Shop BioPure Peptides →
Affiliate Disclosure: PeptideOnline may earn a commission on purchases made through these links. This does not influence our editorial content. Full disclosure →